The U.S. Food and Drug Administration has released a new draft guidance aimed at accelerating the development and approval of highly targeted, individualized therapies for patients with ultra-rare diseases. The proposal outlines a regulatory pathway for sponsors seeking to demonstrate substantial evidence of effectiveness and safety when traditional randomized controlled trials are not feasible due to extremely small patient populations.
The draft guidance was issued jointly by the Center for Biologics Evaluation and Research and the Center for Drug Evaluation and Research. It focuses particularly on genome editing and RNA-based therapies, such as antisense oligonucleotides, while leaving open the possibility that the framework could apply to other tailored therapeutics designed to directly address the specific biological cause of a disease.
Under the proposal, therapies must meet several key criteria. Sponsors are expected to identify the precise disease-causing genetic, cellular, or molecular abnormality and demonstrate that the therapy directly targets the root cause or its proximate biological pathway. The guidance also emphasizes the importance of well-characterized natural history data from untreated patients and confirmation that the therapy successfully engages or edits its intended target. For traditional approval, evidence of clinical improvement, changes in disease progression, or validated biomarkers predictive of benefit would be required.
Federal health leaders framed the guidance as part of a broader effort to modernize regulatory science. Health and Human Services Secretary Robert F. Kennedy, Jr. said the initiative aims to accelerate cures for families, particularly children with ultra-rare diseases. FDA Commissioner Marty Makary described the document as a critical step toward reducing barriers and applying regulatory flexibility for rare disease patients.
The framework—referred to as the “Plausible Mechanism Framework”—was further highlighted by Vinay Prasad, director of CBER, and Tracy Beth Høeg, acting director of CDER. They noted that individualized treatments tailored to unique DNA sequences could potentially be evaluated under master protocols, allowing multiple product variants targeting different mutations in a single gene to be assessed within one overarching trial.
Recognizing the practical challenges of studying ultra-rare conditions, the FDA acknowledged that clinical investigations in this space will often involve small sample sizes. However, results must still be robust enough to rule out chance findings. Regulators indicated that effectiveness determinations will consider disease severity, strength of evidence, and feasibility constraints.
The draft guidance, titled Considerations for the Use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause, is now open for public comment for 60 days following its publication in the Federal Register.
Through this initiative, the FDA signaled its commitment to advancing safe and effective therapies for rare disease patients, ensuring that individuals with uncommon conditions are not left behind in the era of precision medicine.